A study of RCC tumor samples, which included both nccRCC (28.9%) and sarcomatoid (19.4%) histologies, detected TIM-3 expression in 56.4% of all samples, indicating that it is a feasible target across histologic subtypes [166]. The gene discussed is HAVCR2; the disease is neoplasm.